Physician profile
Andrew Stiff
NPI 1053687525
$10,304.74
in general payments reported to CMS, 2019-2025
24 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,971 · 2020: $2,050 · 2021: $98.24 · 2022: $198 · 2023: $181 · 2024: $337 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $8,417.79 | 2019-2020 | |
| Boston Scientific Corporation | $523.86 | 2022-2025 | Watchman Flx, Avvigo Guidance System, Wolverine Coronary Cutting Balloon |
| Janssen Pharmaceuticals, INC | $250.48 | 2019-2023 | Xarelto |
| Cardiovascular Systems INC. | $168.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $143.36 | 2022-2025 | |
| Amgen INC. | $113.07 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $111.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.15 | 2021-2023 | Farxiga, Brilinta |
| La Jolla Pharmaceutical Company | $58.47 | 2021 | |
| Pfizer INC. | $57.50 | 2023-2025 | |
| Abbott Laboratories | $47.48 | 2019-2023 | Cardiomems |
| Esperion Therapeutics, INC. | $47.23 | 2020-2021 | |
| Shockwave Medical, INC | $38.73 | 2025 | |
| Novo Nordisk INC | $38.71 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $32.90 | 2022-2024 | Camzyos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $30.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.91 | 2024 | Jardiance |
| Philips North America LLC | $24.53 | 2024 | (Ck4) Mcot |
| Terumo Medical Corporation | $18.62 | 2019 | |
| Medtronic, INC. | $18.42 | 2024 | Linq II |
| Sanofi-Aventis U.S. LLC | $16.55 | 2022 | |
| Abiomed | $14.80 | 2019 | |
| Chiesi USA, INC. | $13.68 | 2023 | Cleviprex, Kengreal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.59 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.